Glucose metabolism in patients with essential hypertension

被引:114
作者
García-Puig, J
Ruilope, LM
Luque, M
Fernández, J
Ortega, R
Dal-Ré, R
机构
[1] Hosp Univ La Paz, Gen Hosp, Med Interna Serv, Div Internal Med, Madrid 28046, Spain
[2] Hosp Univ 12 Octubre, Hypertens Unit, Madrid, Spain
[3] Hosp Clin Univ, Hypertens Unit, Madrid, Spain
[4] GlaxoSmithKline, Dept Med, Madrid, Spain
关键词
insulin resistance; hypertension; type; 2; diabetes; impaired fasting glucose; impaired glucose tolerance; left ventricular hypertrophy;
D O I
10.1016/j.amjmed.2005.09.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Arterial hypertension is an insulin-resistant condition that has been associated with an increased incidence of diabetes. We assessed the prevalence of glucose abnormalities in a population of patients with essential hypertension. Methods: In this cross-sectional study, 420 consecutively referred essential hypertensive patients were studied at 16 hypertension clinics in university and community hospitals of Spain. Fasting and 2-hour plasma glucose and insulin levels were determined in nondiabetic patients. Results: An abnormal glucose metabolism was diagnosed in 68.5% (95% confidence interval [CI], 63.7%-72.9%) of the patients. Isolated insulin resistance, defined by a homeostasis model assessment-estimated insulin resistance (HOMA-IR) equal to or above 3.8, was shown in 9.3% (95% CI, 6.7%-12.5%); impaired fasting glucose in 11.2% (95% CI, 8.6%-14.7%); impaired glucose tolerance in 22.5% ( 95% CI, 18.5%-26.9%); silent undiagnosed type 2 diabetes in 11.5% (95% CI, 8.6%-14.5%); and known diabetes mellitus in 13.9% (95% CI, 10.4%-17.2%) of the patients. According to the European Group for the Study of Insulin Resistance and the Adult Treatment Program III criteria, the metabolic syndrome was diagnosed in 41.5% (95% CI, 35.9%-47.3%) and 47.9% (95% CI, 43.1%-52.8%) of the patients, respectively. The prevalence of left ventricular hypertrophy (defined by a left ventricular mass index [LVMI] >125 g/m(2)) was 44.2%. The relation between HOMA-IR and LVMI was statistically nonsignificant, and the LVMI values in the HOMA-IR quartiles were similar. Only 27 patients (6.4%) showed good control of cardiovascular risk factors. In most patients (273, 65%; 95% CI, 60.3%-69.4%) 2 or more cardiovascular risk factors were identified as not being under control. Conclusions: Two thirds of the patients attending hypertension clinics with essential hypertension show an abnormal glucose metabolism. The metabolic syndrome can be identified in a substantial number of these patients, and 2 or more cardiovascular risk factors are not controlled in the majority of patients. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:318 / 326
页数:9
相关论文
共 55 条
[1]   Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population [J].
Ascaso, JF ;
Romero, P ;
Real, JT ;
Priego, A ;
Valdecabres, C ;
Carmena, R .
MEDICINA CLINICA, 2001, 117 (14) :530-533
[2]  
Balkau B, 2002, DIABETES METAB, V28, P364
[3]   Screening for type 2 diabetes mellitus in adults: Recommendations and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, P ;
Homer, CJ ;
Johnson, MS ;
Klein, JD ;
Lieu, TA ;
Orleans, CT ;
Peipert, JF ;
Pender, NJ ;
Sin, AL ;
Teutsch, SM ;
Westhoff, C ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (03) :212-214
[4]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[5]   Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study [J].
Castell, C ;
Tresserras, R ;
Serra, J ;
Goday, A ;
Lloveras, G ;
Salleras, L .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1999, 43 (01) :33-40
[6]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[7]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[8]   Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study [J].
de Simone, G ;
Palmieri, V ;
Bella, JN ;
Celentano, A ;
Hong, YL ;
Oberman, A ;
Kitzman, DW ;
Hopkins, PN ;
Arnett, DK ;
Devereux, RB .
JOURNAL OF HYPERTENSION, 2002, 20 (02) :323-331